WP
IRLA

Westmount Partners’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Westmount Partners’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50
Closed -$10.6K – 223
2024
Q1 		$10.6K Sell
50
-1
-2% -$248 ﹤0.01% 212
2023
Q4 		$10.7K Hold
51
– – ﹤0.01% 201
2023
Q3 		$11.4K Hold
51
– – 0.01% 192
2023
Q2 		$15.3K Hold
51
– – 0.01% 186
2023
Q1 		$15.8K Hold
51
– – 0.01% 183
2022
Q4 		$6.47K Buy
+51
New +$8.53K ﹤0.01% 172

Other funds holding IRLA

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Westmount Partners's IRLA Position: Q2 2024 in Review

Westmount Partners sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2024, closing a stake of 50 shares — an estimated $10.6K sold.

Westmount Partners first reported a position in IRLA in Q4 2022 and held it in 6 quarters. The position peaked at $15.8K in Q1 2023. 41 funds tracked by Wall St. Rank hold IRLA as of Q2 2024.

  • Westmount Partners reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Westmount Partners sold 50 IRulya Therapeutics Inc. Common Stock shares in Q2 2024, an estimated $10.6K.
  • Westmount Partners first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2022 and held it in 6 quarters.
  • Westmount Partners's IRulya Therapeutics Inc. Common Stock position peaked at $15.8K in Q1 2023.
  • 41 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2024.

Based on Westmount Partners's 13F filing for Q2 2024, filed 28 Jan 2025.